Home Biosimilar Antibodies Others Others Teplizumab (Anti-CD3e)
For research use only. Not for use in humans.

Teplizumab (Anti-CD3e)

Synonyms: MGA-031; PRV-031

Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD.

Teplizumab (Anti-CD3e)

Quality Control

Batch: Purity: 99% Protein concentration: 9.66mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD.

Product Details

CAS No. 876387-05-2
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07610213 NOT_YET_RECRUITING Drug: Teplizumab Type 1 Diabetes Mellitus (T1DM); Type 1 Diabetes Mellitus; Autoimmune Diabetes Abdullah Kars 2027-01-01 PHASE1
NCT07216391 NOT_YET_RECRUITING Drug: Antithymocyte Globulin (ATG)|Drug: Teplizumab Type 1 Diabetes Mellitus National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2026-07-30 PHASE2
NCT07088068 RECRUITING Drug: Teplizumab Type 1 Diabetes Mellitus Sanofi 2025-08-06 PHASE3
NCT06791291 RECRUITING Drug: Teplizumab Type 1 Diabetes Mellitus Sanofi 2025-07-25 PHASE2
NCT06338553 RECRUITING Drug: Semaglutide (Rybelsus®)|Drug: Placebo Type 1 Diabetes Vanderbilt University Medical Center 2024-06-12 EARLY_PHASE1
NCT05757713 ACTIVE_NOT_RECRUITING Diabetes Mellitus, Type 1 Sanofi 2023-07-25 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-05-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.